Boston Scientific - State-of-the-art: Paclitaxel devices 2025

Femoropopliteal treatment: latest evidence

Addressing endovascular challenges
with new evidence

The results of three highly anticipated studies on drug-eluting devices were shared at Charing Cross 2025:

Eluvia™ Meta-Analysis

Presented by Prof. A. Holden First-of-its-kind systematic meta-analysis.
Compared outcomes across Eluvia™ DES, Zilver PTX, Viabahn and BMS.

Discover long lesion patency

SPORTS RCTs 2-years

Presented by Prof. Gunnar Tepe, Eluvia™ was proved statistically superior compared to BMS and DCB +/- BMS, providing critical insights into treatment strategy performance for complex TASC C/D lesions.

Discover angiographic results

TRUE PTX Eluvia™ subgroup

Analysis showed how Eluvia™ may reduce the odds of amputation by 47% and readmission rates by 23% vs. non-drug devices.

Discover more

Boston Scientific International SA

www.bostonscientific.eu | Tel: +33 1 39 30 97 00

Parc Val Saint Quentin - Bâtiment H | 2 Rue René Caudron | 78960 Voisins-le-Bretonneux

VAT: FR07420668402

References

Presented by:
Holden A. Performance of stenting in femoropopliteal disease: Systemic review and meta-analysis of proportions. London, UK. 23 April 2025.
DeRubertis, Brian, MD. "Polymer-based Drug-ElutingStents Bare Device Therapies for PAD In the Real World: 12-Month Amputation and Readmission Rates in a Large Nation wide Population." London, UK. April 23, 2025.
Tepe, G. SPORTS Trial: Drug Eluting Stent or Primary Bare Nitinol Stent Application versus Drug Coated Balloons in Long SFA Lesions. 23 Apr 2025.

CAUTION

The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com.
Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.
This material not intended for use in France.

PI-2188207-AA
CⲈ 0344

Privacy Policy | Terms of Use

For questions on privacy
Contact our EU Data Protection Officer at: [email protected]
Boston Scientific
c/Ribera del Loira, 46 Edificio 2
28042 Madrid (Spain)

Addressing endovascular challenges with new evidence

Eluvia™ Meta-Analysis

SPORTS RCTs 2-years

TRUE PTX Eluvia™ subgroup

Addressing endovascular challenges
with new evidence